Pharmacodynamic and also genomic marker pens associated with reply to your XPO1/CRM1 inhibitor selinexor (Dupracetam): A report through the pediatric preclinical assessment program | #CDK2-IN-4 #PF-00299804 #LY2603618 #GSK2399872A #TEW-7197 #KPT-8602 #RG-7388 #NSC 122758 #NSC-100880 #LY2228820 #VPA #AG-120 #EDHS-206 #BC-2059 #BU-4061T #LY2606368 #Menin-MLL Inhibitor #GDC-0980 #ABBV-075 #NVP-AUY922 #Repertaxin #IPI-145 #FI-6934 #MK 733
